PharmCADD
PharmCADD is a South Korean biotech company that operates Pharmulator, a SaaS platform combining quantum computing and AI to predict drug compound properties and screen up to 12 million compounds per day for pharmaceutical drug discovery clients.
- Company typePrivate
- Founded2019
- HeadquartersBusan, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
PharmCADD firmographics
Firmographics- Name
- PharmCADD
- Website
- https://pharmcadd.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- PharmCADD is a South Korean biotech company that operates Pharmulator, a SaaS platform combining quantum computing and AI to predict drug compound properties and screen up to 12 million compounds per day for pharmaceutical drug discovery clients.
- Ownership category
- akta.pro rank
PharmCADD industry classification
Industry- Product category
- Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where PharmCADD is headquartered
LocationHeadquarters
- HQ city
- Busan
- HQ country
- South Korea
- HQ region
- Asia
Markets served
PharmCADD business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Pharmulator SaaS Platform: Software-as-a-service platform providing quantum computing and AI-powered drug compound simulation and prediction services to pharmaceutical companies. Revenue generated through platform subscriptions or usage fees for compound screening services.
Go-to-market motion1 record
Distribution channels1 record
PharmCADD product offering
Product offeringCore offering
PharmCADD develops Pharmulator, a SaaS platform that combines quantum computing and artificial intelligence to support drug discovery. The platform is designed for pharmaceutical and biotechnology research teams that need computational modeling and prediction of molecular behavior to accelerate candidate identification and reduce wet-lab experimentation.
Differentiator
Problem solved
Functional benefit
Brands
- Pharmulator: SaaS platform combining quantum computing and AI to predict and simulate drug compound properties for identifying new drug candidates
Products and services
- Pharmulator
Quantifiable outcome
- Drug candidates identified in minutes rather than years
- +2 more outcomes
Companies that use PharmCADD
Customer profileSegments1 record
Ideal customer profiles1 record
PharmCADD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
PharmCADD partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- IBM QuantumcorePharmCADD is collaborating with IBM Quantum to build hybrid quantum computing platforms for drug discovery applications. This partnership provides access to IBM's quantum computing infrastructure and expertise to enhance PharmCADD's Pharmulator platform capabilities.
- Seoul National University of Science and TechnologycorePharmCADD is collaborating with Seoul National University of Science and Technology to build hybrid quantum computing platforms. The partnership leverages academic research expertise in quantum computing and computational chemistry for drug discovery applications.
Scale indicators3 records
PharmCADD competitors and assessment
Company assessmentEmerging players
- Atomwise: AI-based small molecule drug design platform using structure-based ML models for hit identification. Comparable technology positioning and pharma enterprise GTM, differentiated by ML rather than quantum methods.
- Insitro: ML-driven drug discovery platform combining high-throughput biology with predictive models. Comparable as an emerging AI-first discovery platform targeting pharma partnerships.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput experimental data with ML models. Comparable in target customer (large pharma) and AI-first discovery thesis, though focused on phenotypic/ML rather than quantum mechanical approaches.
- Cyrus Biotechnology: Computational protein design and engineering platform combining physics-based modeling with ML. Partially overlapping in computational chemistry approach for biologics and small molecules.
Broad incumbents
- Schrödinger, Inc. Industry-leading physics-based molecular simulation platform for drug discovery and materials science. A broad incumbent in computational chemistry/CADD that pharma buyers already procure, making it the primary incumbent PharmCADD must displace or complement.
- Dassault Systèmes BIOVIA: Enterprise scientific software suite including molecular modeling, lab informatics, and discovery workflows. Broad incumbent serving global pharma R&D with established procurement relationships.
Direct peers
- XtalPi: Closest direct competitor — combines quantum physics, AI, and high-performance computing for drug discovery and crystal structure prediction. Operates a SaaS-style platform serving global pharma, directly comparable in technology stack and customer base.
- Chemical Computing Group (CCG, Molecular Operating Environment): Provider of the MOE (Molecular Operating Environment) software platform for CADD, including pharmacophore modeling and docking. Long-standing direct CADD peer serving pharma and academic users.
- OpenEye Scientific (Cadence): Molecular modeling and cheminformatics software for drug discovery, including force-field-based simulation and structure-based design. Direct CADD peer with overlapping physics-based methodology.
Others
- IBM Quantum: Strategic technology partner rather than competitor, but operates the Qiskit-based quantum ecosystem that PharmCADD's hybrid platform depends on. Listed as an 'OTHERS' peer given its enabling infrastructure role.
Market position
Customer concentration
PharmCADD social profiles
Digital presencePharmCADD financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmCADD leadership team
Management profileNumber of profiles
Profiles2 records
PharmCADD funding detail
Funding detailFunding overview
Funding rounds4 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmCADD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmCADD
What does PharmCADD do?
PharmCADD develops Pharmulator, a SaaS platform that combines quantum computing and artificial intelligence to support drug discovery. The platform is designed for pharmaceutical and biotechnology research teams that need computational modeling and prediction of molecular behavior to accelerate candidate identification and reduce wet-lab experimentation.
Is PharmCADD a public or private company?
PharmCADD is a private company. It is classified as venture growth investor backed and is currently operating.
When was PharmCADD founded?
PharmCADD was founded in 2019. It employs 51 to 100 people.
Where is PharmCADD based?
PharmCADD is headquartered in Busan, South Korea, in the Asia region.
How does PharmCADD make money?
One revenue line is on record: pharmulator SaaS Platform.
Who are PharmCADD's main competitors?
Emerging players on record are Atomwise, Insitro, Recursion Pharmaceuticals and Cyrus Biotechnology. Broad incumbents are Schrödinger, Inc. and Dassault Systèmes BIOVIA. Direct peers are XtalPi, Chemical Computing Group (CCG, Molecular Operating Environment) and OpenEye Scientific (Cadence). IBM Quantum is listed as an others.
Does PharmCADD have an API?
No public API is recorded for PharmCADD.
What industry is PharmCADD in?
PharmCADD's product category is Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAE, Cheminformatics & Molecular Modeling / CADD, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 7372.